Parameters
|
All patients (n = 172)
|
Patients without the primary outcome (n = 129)
|
Patients with the primary outcome (n = 43)
|
P value
|
---|
Age (years)
|
56.4 ± 14.3
|
57.0 ± 14.6
|
54.8 ± 13.5
|
0.398
|
Male gender, n (%)
|
116 (67.4)
|
85 (65.9)
|
31 (72.1)
|
0.452
|
Mean arterial pressure (mmHg)
|
84 ± 13
|
86 ± 13
|
80 ± 12
|
0.015
|
Hypertension, n (%)
|
58 (33.7)
|
44 (34.1)
|
14 (32.6)
|
0.852
|
Diabetes mellitus, n (%)
|
36 (20.9)
|
25 (19.4)
|
11 (25.6)
|
0.387
|
Dyslipidemia, n (%)
|
11 (6.4)
|
8 (6.2)
|
3 (7.0)
|
0.857
|
Current smoker, n (%)
|
49 (28.5)
|
37 (28.7)
|
12 (27.9)
|
0.734
|
Chronic kidney diseasea, n (%)
|
31 (18.0)
|
21 (16.3)
|
10 (23.3)
|
0.303
|
Previous CVA, n (%)
|
4 (2.3)
|
1 (0.8)
|
3 (7.0)
|
0.049
|
Body mass index (kg/m2)
|
24.0 ± 4.5
|
24.2 ± 4.5
|
23.5 ± 4.4
|
0.347
|
ECG at baseline
| | | | |
Heart rate (bpm)
|
83 ± 20
|
84 ± 19
|
83 ± 22
|
0.883
|
Left bundle-branch block, n (%)
|
31 (18.0)
|
23 (17.8)
|
8 (19.0)
|
0.859
|
QRS duration (ms)
|
113 ± 29
|
112 ± 30
|
117 ± 29
|
0.305
|
Laboratory data
| | | | |
Serum creatinine (mg/dl)
|
0.97 ± 0.27
|
0.96 ± 0.25
|
1.01 ± 0.31
|
0.247
|
Na (mmol/l)
|
139.6 ± 3.3
|
140.2 ± 2.8
|
137.6 ± 3.8
|
< 0.001
|
ln(NT-proBNP) (pg/ml)
|
7.22 ± 1.27
|
7.08 ± 1.29
|
7.60 ± 1.16
|
0.022
|
Cardiac medications
| | | | |
Beta-blockers, n (%)
|
120 (69.8)
|
87 (67.4)
|
33 (76.7)
|
0.250
|
ACE-inhibitors/ARB, n(%)
|
134 (77.9)
|
104 (80.6)
|
39 (90.7)
|
0.126
|
Spironolactone, n (%)
|
101 (58.7)
|
74 (57.4)
|
27 (62.8)
|
0.531
|
Diuretics, n (%)
|
125 (72.7)
|
93 (72.1)
|
32 (74.4)
|
0.767
|
Digoxin, n (%)
|
33 (19.2)
|
21 (16.3)
|
12 (27.9)
|
0.094
|
- Primary outcome: all-cause death, heart transplantation during follow-up. Values are mean ± SD, n(%)
- aChronic kidney disease was defined as eGFR < 60 ml/min/1.73m2, calculated using the 4-component MDRD study equation
- Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blockers, BNP B-type natriuretic peptide, CVA cerebrovascular accident ECG electrocardiography